Barclays
ABOS icon

Barclays’s Acumen Pharmaceuticals ABOS Stock Holding History

Barclays’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$72.4K Buy
30,679
+688
+2% +$1.75K ﹤0.01% 4168
2025
Q4 		$63.3K Hold
29,991
– – ﹤0.01% 4696
2025
Q3 		$51.3K Hold
29,991
– – ﹤0.01% 4761
2025
Q2 		$34.8K Sell
29,991
-42,274
-58% -$45.4K ﹤0.01% 4759
2025
Q1 		$79.5K Sell
72,265
-20,817
-22% -$29.7K ﹤0.01% 4475
2024
Q4 		$160K Buy
93,082
+31,085
+50% +$74.8K ﹤0.01% 4406
2024
Q3 		$154K Buy
61,997
+40,551
+189% +$110K ﹤0.01% 4426
2024
Q2 		$51.9K Sell
21,446
-25,864
-55% -$82.3K ﹤0.01% 4199
2024
Q1 		$192K Sell
47,310
-37
-0.1% -$139 ﹤0.01% 4137
2023
Q4 		$182K Buy
47,347
+24,922
+111% +$74K ﹤0.01% 4459
2023
Q3 		$93.1K Sell
22,425
-2,969
-12% -$18.3K ﹤0.01% 3625
2023
Q2 		$122K Sell
25,394
-558
-2% -$2.67K ﹤0.01% 3487
2023
Q1 		$105K Sell
25,952
-8,509
-25% -$44.4K ﹤0.01% 4148
2022
Q4 		$186K Buy
34,461
+300
+0.9% +$2.02K ﹤0.01% 3880
2022
Q3 		$342K Buy
34,161
+27,437
+408% +$157K ﹤0.01% 2898
2022
Q2 		$32K Sell
6,724
-5,093
-43% -$19.1K ﹤0.01% 4214
2022
Q1 		$46K Buy
+11,817
New +$64.3K ﹤0.01% 4145

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Barclays's ABOS Position: Q1 2026 in Review

Barclays increased its Acumen Pharmaceuticals (ABOS) stake by 2.3% in Q1 2026, buying an estimated $1.75K and bringing the position to 30,679 shares worth $72.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4168.

Barclays first reported a position in ABOS in Q1 2022 and has held it in 17 quarters since. The position peaked at $342K in Q3 2022. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

  • Barclays held 30,679 shares of Acumen Pharmaceuticals worth $72.4K as of Q1 2026.
  • Barclays bought 688 Acumen Pharmaceuticals shares in Q1 2026, an estimated $1.75K.
  • Acumen Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4168 holding.
  • Barclays first reported a position in Acumen Pharmaceuticals in Q1 2022 and has held it in 17 quarters since.
  • Barclays's Acumen Pharmaceuticals position peaked at $342K in Q3 2022.
  • 84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.